US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
USOTC
PolyPeptide Group AG (PK) (PLYGF) 銘柄情報

PolyPeptide Group AG (PK) (PLYGF)

43.00

0.00

(0.00%)

終了 7月11日 5:00AM

PolyPeptide Group AG (PK) (PLYGF) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

43.00

( - )

買値

0.0101

売値

557.20

出来高

-

平均取引量 (3 か月)

US$ 75,231

財務取引量

-

0.00 日の範囲 0.00

31.50 52 週間の範囲 50.00

時価総額

企業価値

1.685B

前日終値

43.00

始値

-

時刻

最終取引時間

VWAP

-

歳入

389.33M

純利益

-21.17M

発行済株式数

33,006,565

浮動株比率 (%)

39.26%

機関投資家保有比率 (%)

9.56%

配当利回り

PER

-76.39

株価売上高倍率 (PSR)

4.16

1 株当たり利益 (EPS)

-0.64

ベータ

1.04

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers po... PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, pharmaceutical, and biotech companies. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V. 詳細を表示

セクター

-

業界

-

ウェブサイト

www.polypeptide.com

本社

Baar, Switzerland

設立

2026

PolyPeptide Group AG (PK) is listed in the sector of the その他OTC with ticker PLYGF. The last closing price for PolyPeptide (PK) was US$43. Over the last year, PolyPeptide (PK) shares have traded in a share price range of US$ 31.50 to US$ 50.00.

PolyPeptide (PK) currently has 33,006,565 shares in issue. The market capitalisation of PolyPeptide (PK) is US$1.42 billion. PolyPeptide (PK) has a price to earnings ratio (PE ratio) of -76.39.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	-2.5	-5.49450549451	45.5	50	43	68	47.07407407	CS
26	8.75	25.5474452555	34.25	50	31.5	202	39.33573496	CS
52	8.75	25.5474452555	34.25	50	31.5	127	38.45501889	CS
156	8.75	25.5474452555	34.25	50	31.5	127	38.45501889	CS
260	8.75	25.5474452555	34.25	50	31.5	127	38.45501889	CS

PLYGF - Frequently Asked Questions (FAQ)

What is the current PolyPeptide Group AG (PK) share price?

The current share price of PolyPeptide Group AG (PK) is US$ 43.00

How many PolyPeptide Group AG (PK) shares are in issue?

PolyPeptide Group AG (PK) has 33,006,565 shares in issue

What is the market cap of PolyPeptide Group AG (PK)?

The market capitalisation of PolyPeptide Group AG (PK) is USD 1.42B

What is the 1 year trading range for PolyPeptide Group AG (PK) share price?

PolyPeptide Group AG (PK) has traded in the range of US$ 31.50 to US$ 50.00 during the past year

What is the PE ratio of PolyPeptide Group AG (PK)?

The price to earnings ratio of PolyPeptide Group AG (PK) is -76.39

What is the cash to sales ratio of PolyPeptide Group AG (PK)?

The cash to sales ratio of PolyPeptide Group AG (PK) is 4.16

What is the registered address of PolyPeptide Group AG (PK)?

The registered address for PolyPeptide Group AG (PK) is Neuhofstrasse 24, Baar, Zug, 6340

What is the PolyPeptide Group AG (PK) website address?

The website address for PolyPeptide Group AG (PK) is www.polypeptide.com

shajandr

shajandr 3分前

Roofie the prison janitor.

jjjjjjjj

jjjjjjjj 10分前

https://ih.advfn.com/stock-market/USOTC/medical-marijuana-pk-MJNA/trades?_gl=1*1kzkgjy*_gcl_au*MTI1NDQyNTM1NS4xNzMxNjA2NTY3
IT IS DAMNED IF IT GOES UP, DAMNED IF IT GOES DOWN!
Which is it??? I repeat: IT IS DAMNED IF IT GOES UP. DAMNED IF IT GOES DOWN! Is today Mond

Kool Aid Man

Kool Aid Man 10分前

Has the bank said "no money was lost"? Then why are they suing?

rosemountbomber

rosemountbomber 31分前

It is the consensus view because company management and the FDA have not given us reason to believe otherwise. As far as the AI take in your following post how ridiculous that the 2nd CRL to cite the same deficiencies as the first. They never did a second inspection to discover those deficiencies.

Genz2

https://www.macrumors.com/2026/07/09/apple-prismml-larger-on-device-ai-models/

Has Tesla/SpaceXAI thought about working with a company like PrismML so that they could efficiently run Grok/MacroHard and use less memory in Dell, HP or Lenovo computers? The PrismML could reduce the memor

Slojab

Slojab 33分前

Pretty ridiculous, huh? You should be able to have a negative market cap. 🤣

smoki

F’ing A ….blasting off get your free ride NOW!!! $$$$$$$$$ …Blozf goos Blo ^^^^^^^^^^^^:))))))

BahamaPete

BahamaPete 42分前

Thanks OCKHAM's RAZOR, I added your links to my DD post. Go $TKOI

Helter Skelter

Helter Skelter 52分前

😆 "accurately captures one of the most critical underappreciated alliances..."

https://investorshub.advfn.com/uimage/uploads/2026/7/10/opnhmBB_Can_u_say_MONOPOLY_071026.png

🤑 $BB Where Nvidia Goes We Go $NVDA 🤑

Twiggs333

Twiggs333 58分前

CMPS Compass Pathways: A Structural Mispricing in Plain Sight?

Extremely good explanation of the value of this company by a Stanford Professor.

https://x.com/kevin__mak/status/2075541715272790373

Popeye

Popeye 59分前

Yeah, agreed. That was a shot of the dark guess of the discount for the Reg A and .08 would certainly move the numbers in the favor of the shareholder.
Unknowns are 1. What will the discount be and 2. How much will Korenko raise? (Doesn’t have to raise the entire $9 million now - maybe raise

Twiggs333

Twiggs333 1時間前

Compass Pathways: A Structural Mispricing in Plain Sight?

https://x.com/kevin__mak/status/2075541715272790373

CA Market News

CA Market News 1時間前

Lion One Announces Closing of Second Tranche of Non-Brokered Private Placement of Convertible Debenture Units and Units for Aggregate Gross Proceeds of $17.5 MillionJuly 10, 2026 11:14 PM
Newsfile

Genz2

Genz2 1時間前

Sorry, misspelled Greg’s last name in the previous post!!! It should be Kazmierczak!!

Gus1212

Gus1212 1時間前

If this rejection theory is correct, I believe it was just a tactic to stall our approval process.
Sounds too simple, doesn't it!

Maybe paid for by you know who, big pharma.

They all know that DCVAX works; they are not dummies.
Why did they stall? Cou

Whalatane

Whalatane 1時間前

A Fable 5 analysis
Synthesized FDA timeline risks, TDAPA reimbursement implications, and dilution concernsSynthesized FDA timeline risks, TDAPA reimbursement implications, and dilution concernsGood context to layer in.
Here's the deeper risk breakdown on those three fronts.

LTR

I think a suitable punishment for these guys would be to lock them up in ILT's vault and throw away the key.

Real McCoy

Real McCoy 1時間前

Well yeah this one has the most lies.

3rd attempt: you ok with lies, yes or no?

pos_stock_hoarder

pos_stock_hoarder 2時間前

New York Dolls - Looking for a Kiss

https://youtu.be/GvmvMFXWzc8

Genz2

Genz2 2時間前

https://techcrunch.com/2026/07/10/us-cyber-agency-cisa-had-to-build-its-incident-playbook-during-the-incident-agency-reveals/

According to Krebs, the researcher tried to alert the contractor but didn’t hear back. Only after Krebs contacted CISA did the agency take the repository offli

boston127

boston127 2時間前

Hey,

Thanks for the links you sent me. My PC blocked all of the URLs due to malware protection. I'm still in GNIS and the other one. I was up but they have dive bombed quite rapidly. Now, in the RED. Both companies are interesting.

LTR

I have an idea AF may turn up in discovery when the dots are lined up and connected. AF may look to be a witness in order to avoid being a defendent.

PolyPeptide (PK)

Agf Global Real Assets C...

Plant Veda Foods

Pioneer Natural Resources

Southern Cross Explorati...

Coinbase Global

UK Auction Gilt British ...

Bmo Asset Allocation Fun...

Sub-class A-49 3.661% Bd...

First Trust Nasdaq Oil a...

Axalta Coating Systems

1.375% until 12jun2030

A2Z Smart Technologies

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。